CASP3 and B-cell chronic lymphocytic leukemia: In the case of sample CLL-67 (panel A), the combined treatment (quercetin along with rTRAIL) increases PARP degradation compared with single treatments, whereas in the second case (panel B, corresponding to CLL-44), the apoptotic effect of quercetin monotreatment is prevalent, as shown in Table 2 in terms of cell viability, caspase-3 activation and annexin V exposure.